CCL13

Overview

CCL13 (C-C Motif Chemokine Ligand 13; also known as MCP-4) is a monocyte/macrophage chemoattractant chemokine. Together with CCL2, CCL7, and CCL8, it is upregulated in pretreatment melanoma tumors exhibiting innate resistance to anti-PD-1 checkpoint blockade, as part of the IPRES transcriptional resistance signature.

Alterations observed in the corpus

• CCL13 was identified as a monocyte/macrophage chemoattractant up-regulated in non-responders to anti-PD-1 therapy in melanoma, part of the IPRES innate resistance transcriptional signature PMID:26997480.

Cancer types (linked)

• SKCM: CCL13 overexpression in pretreatment melanoma biopsies is enriched in tumors that fail to respond to anti-PD-1 therapy; co-upregulated with CCL2, CCL7, CCL8 PMID:26997480.

Co-occurrence and mutual exclusivity

• Co-expressed with CCL2, CCL7, CCL8, VEGFA, VEGFC, IL10, and mesenchymal transition transcripts (AXL, ROR2, WNT5A, LOXL2, TWIST2) in IPRES-positive melanoma non-responders PMID:26997480.

Therapeutic relevance

• As a component of the IPRES signature, CCL13 overexpression in pretreatment biopsies identifies patients unlikely to respond to anti-PD-1 monotherapy; combination strategies targeting macrophage recruitment are under investigation PMID:26997480.

Open questions

• Prospective validation of CCL13 and the broader IPRES signature in independent cohorts before clinical implementation PMID:26997480.

Sources

• PMID:26997480

This page was processed by crosslinker on 2026-05-14.